Solomon R, Dubey A
Renal Division, Westchester County Medical Center, Valhalla, NY.
Am J Kidney Dis. 1992 May;19(5):420-6. doi: 10.1016/s0272-6386(12)80948-6.
Seven subjects with end-stage renal disease (ESRD) who were anuric and dialysis-dependent were studied during a 28-hour interdialytic period to assess changes in plasma potassium. Plasma potassium, glucose, magnesium, aldosterone, and cortisol were measured every 4 hours. Eight normal subjects were similarly treated. Subjects with ESRD had a progressive increase in plasma potassium, in contrast to normal subjects who exhibited a characteristic diurnal variation. In ESRD, diltiazem significantly reduced the rate of increase in plasma potassium compared with placebo and resulted in a significantly lower net increase in potassium over the entire 28-hour period. Diltiazem did not affect plasma potassium in normal subjects. Diltiazem did not affect plasma aldosterone, cortisol, glucose, or magnesium. In conclusion, diltiazem reduced the rate of increase of plasma potassium during a 28-hour interdialytic period.
对7名处于终末期肾病（ESRD）且无尿并依赖透析的受试者在28小时的透析间期进行研究，以评估血浆钾的变化。每4小时测量一次血浆钾、葡萄糖、镁、醛固酮和皮质醇。8名正常受试者接受类似治疗。与呈现特征性昼夜变化的正常受试者相比，ESRD受试者的血浆钾呈进行性升高。在ESRD患者中，与安慰剂相比，地尔硫卓显著降低了血浆钾的升高速率，并导致在整个28小时期间钾的净增加显著降低。地尔硫卓对正常受试者的血浆钾没有影响。地尔硫卓不影响血浆醛固酮、皮质醇、葡萄糖或镁。总之，地尔硫卓在28小时的透析间期降低了血浆钾的升高速率。
